B. Bolstad

Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study

Sten Nilsson, Lars Franzén, Christopher Parker et al. · The Lancet Oncology · 2007 · 493 citations

Medicine, Oncology, Radiation Oncology +15

Reliability of goniometric measurements and visual estimates of hip ROM in patients with osteoarthrosis

Inger Holm, B. Bolstad, Teresa Lütken et al. · Physiotherapy Research International · 2000 · 162 citations

Medicine, Orthopaedic Surgery, Orthopedic Surgery +14

Overall Survival Benefit of Radium-223 Chloride (Alpharadin™) in the Treatment of Patients with Symptomatic Bone Metastases in Castration-resistant Prostate Cancer (CRPC): a Phase III Randomized Trial (ALSYMPCA)

Chris Parker, Daniel Heinrich, Joe M. O’Sullivan et al. · European Journal of Cancer · 2011 · 137 citations

Medicine, Oncology, Radiation Oncology +17

Two-Year Survival Follow-Up of the Randomized, Double-Blind, Placebo-Controlled Phase II Study of Radium-223 Chloride in Patients With Castration-Resistant Prostate Cancer and Bone Metastases

Sten Nilsson, Lars Franzén, Christopher Parker et al. · Clinical Genitourinary Cancer · 2012 · 119 citations

Medicine, Oncology, Radiation Oncology +17

Five- to 10-Year Prospective Follow-Up of Wrist Arthroplasty in 56 Nonrheumatoid Patients

Ole Reigstad, Trygve Holm‐Glad, B. Bolstad et al. · The Journal Of Hand Surgery · 2017 · 88 citations

Medicine, Orthopaedic Surgery, Orthopedic Surgery +12